Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · IEX Real-Time Price · USD
3.035
+0.015 (0.50%)
At close: Apr 26, 2024, 3:59 PM
3.030
-0.005 (-0.16%)
After-hours: Apr 26, 2024, 4:00 PM EDT
Cellectar Biosciences Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for CLRB stock have an average target of 20, with a low estimate of 12 and a high estimate of 28. The average target predicts an increase of 558.98% from the current stock price of 3.04.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CLRB stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Strong Buy Maintains $20 → $28 | Strong Buy | Maintains | $20 → $28 | +822.57% | Mar 28, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $11 → $12 | Buy | Reiterates | $11 → $12 | +295.39% | Mar 28, 2024 |
| Roth MKM | Roth MKM | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +558.98% | Mar 4, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3 → $4 | Strong Buy | Maintains | $3 → $4 | +31.80% | Nov 4, 2022 |
| Oppenheimer | Oppenheimer | Buy Initiates $55 | Buy | Initiates | $55 | +1,712.19% | Jul 18, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
45.16M
EPS This Year
-1.67
from -3.11
EPS Next Year
-0.59
from -1.67
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 93.3M | 160.4M | 242.6M | 319.3M |
| Avg | n/a | 45.2M | 94.7M | 153.5M | 246.1M |
| Low | n/a | 19.7M | 51.2M | 105.6M | 175.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 255.2% | 156.0% | 108.0% |
| Avg | - | - | 109.8% | 62.0% | 60.4% |
| Low | - | - | 13.5% | 11.5% | 14.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.03 | 0.14 | 0.88 | 3.47 | 5.03 |
| Avg | -1.67 | -0.59 | 0.16 | 2.25 | 3.39 |
| Low | -2.14 | -1.27 | -0.39 | 1.09 | 2.42 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 2,023.2% | 123.6% |
| Avg | - | - | - | 1,278.1% | 50.6% |
| Low | - | - | - | 566.5% | 7.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.